The overall goal of this Program Project is to develop novel, safe, and effective M. tuberculosis (Mtb)- derived vaccines for the prevention of tuberculosis (TB). Project 3 will focus on investigating the roles of two components of the tuberculous granuloma - B cells and tumor necrosis factor (TNF) - in their ability to augment immunogenicity of anti-TB vaccines. The proposed program derives from data generated in the last funding period. The B cell-deficient ?MT mouse studies revealed that these lymphocytes are required for the optimal control of acute TB. In chronic infection, T cell response (proliferation and IFNy production) in ?MT mice Is remarkably altered. Studies using mice deficient in specific Fey receptors (FcyR) have provided evidence that immune complex (IC) can modulate anti-TB cellular immunity. These are compelling evidence that B cells can regulate T cell response in TB infection. Further, a potent M. smegmatis-derived vaccine IKEPLUS, while highly effective in immunizing wildtype mice against Mtb challenge, failed to protect B cell- deficient animals. Project 3 will characterize the roles of B cells in the development of anti-TB immunity and to test the hypotheses that: i) Specific functions of B cells contribute significantly to the host immune response to Mtb;ii) B cells are required for the development of effective T cell response in TB, including the CD4 T cell memory compartment;iii) B cells are essential for the development of optimal vaccine- engendered protection;and iv) IC can be exploited to augment anti-TB immunity. In the TNF study, we have identified Mtb cosimd clones capable of downregulating macrophage TNF production. We will test the hypothesis that disruption of the TNF-downregulating genes will generate strains that are able to augment macrophage TNF production during infection, thereby enhancing immunogenicity by virtue of their ability to promote phagosome maturation and apoptosis, two processes that can augment T cell immunity. In sum. Project 3 seeks to identify components of the B cell response and TNF-downregulating Mtb genes that can augment immunogenicity of vaccine candidates. These components, when identified, will be incorporated into existing safe and effective Mtb-derived platforms (developed In the last funding period) to further enhance the efficacy of candidate anti-TB vaccines, the overall goal of the P01. Thus, there will be close interactions between Project 3 and the other components of the Program Project. Finally, the Animal, Flow Cytometry, and Administrative Cores will all be utilized extensively by the program proposed in Project 3.

Public Health Relevance

Project 3, an integral part of the PO1, seeks to identify components of B cell immunity and TNF- downregulating genes that can be targeted to enhance host Immunity against Mtb. Identificaion of such factors will guide the rationale design of safe and effective Mtb-derived attenuated vaccine candidates with high level of immunogenicity that can effectively engender protection against the tubercle bacillus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI063537-09
Application #
8690741
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2014-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
City
Bronx
State
NY
Country
United States
Zip Code
10461
Carreño, Leandro J; Saavedra-Ávila, Noemí A; Porcelli, Steven A (2016) Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clin Transl Immunology 5:e69
Olsen, Aaron; Chen, Yong; Ji, Qingzhou et al. (2016) Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines. MBio 7:
Vergnolle, Olivia; Xu, Hua; Tufariello, JoAnn M et al. (2016) Post-translational Acetylation of MbtA Modulates Mycobacterial Siderophore Biosynthesis. J Biol Chem 291:22315-22326
Foreman, Taylor W; Mehra, Smriti; LoBato, Denae N et al. (2016) CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc Natl Acad Sci U S A 113:E5636-44
Prados-Rosales, Rafael; Carreño, Leandro J; Weinrick, Brian et al. (2016) The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis. J Infect Dis 214:426-37
Ng, Tony W; Saavedra-Ávila, Noemí A; Kennedy, Steven C et al. (2015) Current efforts and future prospects in the development of live mycobacteria as vaccines. Expert Rev Vaccines 14:1493-507
Achkar, Jacqueline M; Chan, John; Casadevall, Arturo (2015) B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 264:167-81
Berney, Michael; Berney-Meyer, Linda; Wong, Ka-Wing et al. (2015) Essential roles of methionine and S-adenosylmethionine in the autarkic lifestyle of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 112:10008-13
Petro, Christopher; González, Pablo A; Cheshenko, Natalia et al. (2015) Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife 4:
Achkar, Jacqueline M; Chan, John; Casadevall, Arturo (2015) Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med 5:a018432

Showing the most recent 10 out of 58 publications